Latest Period
Q4 2025
Security Snapshot
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 Institutional Ownership
CUSIP: 89422GAA5
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
33
Principal
$316,740,000
Price (% of par)
142.2%
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Debt / NOTE 2.250% 3/0
- Market price (% of par)
- 115.72%
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F principal
- $316,740,000
- Total reported market value
- $451,855,340
- Principal change
- +$44,363,646
- Market value change
- +$76,789,651
- Number of holders
- 33
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 is tracked under CUSIP 89422GAA5.
- 33 institutions reported positions in Q4 2025.
- Schedule 13D/13G significant owner rows are not currently available.
What Changed
- Holder count moved from 33 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $451,855,340 to $394,106.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 33 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 89422GAA5?
CUSIP 89422GAA5 identifies 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89422GAA5:
As of 31 Dec 2025, 33 institutional investors reported holding $316,740,000 in principal (par value) of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0.
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 across Reporting Periods
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | $366,000 | $394,106 | +$342,413 | 115.72% | 2 |
| 2025 Q4 | $316,740,000 | $451,855,340 | +$76,789,651 | 142.2% | 33 |
| 2025 Q3 | $272,401,354 | $307,917,277 | +$569,773 | 112.88% | 29 |
| 2025 Q2 | $279,664,978 | $303,344,890 | +$1,782,692 | 95.39% | 26 |
| 2025 Q1 | $277,011,293 | $276,983,110 | +$13,929,020 | 99.8% | 28 |
| 2024 Q4 | $264,062,863 | $250,352,690 | +$9,069,609 | 95.24% | 21 |
| 2024 Q3 | $257,683,037 | $224,077,029 | +$11,645,577 | 86.4% | 25 |
| 2024 Q2 | $253,865,742 | $203,588,240 | -$12,098,839 | 64.79% | 18 |
| 2024 Q1 | $273,167,017 | $213,304,940 | -$34,119,308,890 | 63.47% | 18 |
| 2023 Q4 | $334,700,000 | $220,380,890 | +$27,118,701 | 66.0% | 20 |
| 2023 Q3 | $293,624,167 | $216,434,339 | +$1,578,777 | 64.72% | 22 |
| 2023 Q2 | $302,112,167 | $244,546,345 | -$10,623,621 | 81.08% | 21 |
| 2023 Q1 | $312,983,167 | $325,418,603 | +$10,031,881 | 98.3% | 21 |
| 2022 Q4 | $301,166,967 | $274,825,761 | -$26,924,802 | 91.19% | 21 |
| 2022 Q3 | $282,429,300 | $289,316,637 | -$825,518 | 102.07% | 23 |
| 2022 Q2 | $239,416,100 | $244,284,801 | -$22,593,875 | 100.32% | 21 |
| 2022 Q1 | $257,273,349 | $279,703,965 | +$279,703,965 | 106.45% | 23 |